// App-Quantinova.ai

PB0900 : Joint Health Outcomes in Patients with Hemophilia A Receiving Antihemophilic Factor (Recombinant) in a Real-World Setting: Results of a 6-Year Interim Analysis of the AHEAD International Study

Researchers

Presenter

  • M.C. Ozelo

Principal Investigators

  • E. Santagostino

  • R. Klamroth

  • B. Guillet

  • K. Khair

  • D.A. Tsakiris

  • J. Botha

  • A. Fernandez

  • L. Tang

  • J. Oldenburg

Medical Centers

  • University of Campinas, Sao Paulo, Brazil

  • Foundation IRCCS Ca’ Granda, Maggiore Hospital Policlinico, A. Bianchi Bonomi Hemophilia and Thrombosis Center, Milan

  • Vivantes Klinikum Am Friedrichshain, Berlin, Germany

  • Univ Hosp of Rennes, Rennes, France

  • Great Ormond Street Hospital, London, United Kingdom

  • University Hospital Basel, Basel, Switzerland

  • Shire International GmbH, a Takeda company, Zug, Switzerland

  • Bonn University, Bonn, Germany

Locations

  • Brazil

  • Italy

  • Germany

  • France

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • Antihemophilic factor

  • FVIII

Outcome

  • N/A

Study Design

  • Non Interventional

  • Multinational

  • Multicenteric

  • Prospective

Phase

  • NA

Study Id's

  • NCT02078427

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved